Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United States and the first product to launch for this indication since Eylea in 2011. Beovu offers the potential for dosing once every 12 weeks immediately after the first three monthly doses, giving the product a dosing advantage over Lucentis and Eylea in its product labeling. Additionally, Beovu was found to be superior to Eylea in improving some anatomical outcomes in pivotal clinical trials. A competitive price from Novartis, coupled with the possibility of a less-burdensome dosing frequency, will likely ease Beovu’s incorporation into clinical practice. This report provides a snapshot of Beovu’s performance based on physician responses three months after its launch.
Geography: United States
Primary Research: Survey of 75 U.S. ophthalmologists / retinal specialists in January 2020
Key metrics included: Unaided and aided awareness of Beovu; familiarity with and impressions of Beovu; prescriber and nonprescriber profiles; willingness to prescribe Beovu; performance of Beovu on key attributes; sales representative visit frequency, reach, and effectiveness; benchmarking against Eylea
DRG’s Special Topics reports assess key trends in dynamic disease areas. Here we provide a snapshot of Beovu’s performance at three months postlaunch in the U.S. wet AMD market. Specifically, we assess U.S. physicians’ awareness, perceptions, and usage of Beovu, as well as its current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts by Novartis, prescriber and nonprescriber profiles, and benchmarking against Eylea three months after it launched for wet AMD.